Picture of Forum Markets, logo

FRMM Forum Markets, News Story

0.000.00%
us flag iconLast trade - 00:00
FinancialsSpeculativeSmall CapSucker Stock

Brief: 180 Life Sciences Provides Follow-Up Information On Oxford University And The Company’S Successful Dupuytren’S Phase 2B Clinical Trial Results

Dec 6 (Reuters) - 180 Life Sciences Corp  ATNF.O :
    * 180 LIFE SCIENCES PROVIDES FOLLOW-UP INFORMATION ON OXFORD
UNIVERSITY AND THE COMPANY’S SUCCESSFUL DUPUYTREN’S PHASE 2B
CLINICAL TRIAL RESULTS
    * 180 LIFE SCIENCES CORP - BOTH PRIMARY AND SECONDARY
ENDPOINTS
FROM PHASE 2B CLINICAL TRIAL FOR DUPUYTREN'S DISEASE WERE
STATISTICALLY SIGNIFICANT
    * 180 LIFE SCIENCES CORP - INITIAL MEETINGS WITH FDA AND
MHRA
CURRENTLY PLANNED FOR H1 2022

Source text for Eikon:  ID:nGNX8wW8zc 
Further company coverage:  ATNF.O 

 ((reuters.briefs@thomsonreuters.com;))

Recent news on Forum Markets,

See all news